Cargando…

High Levels of Adherence and Viral Suppression in a Nationally Representative Sample of HIV-Infected Adults on Antiretroviral Therapy for 6, 12 and 18 Months in Rwanda

BACKGROUND: Generalizable data are needed on the magnitude and determinants of adherence and virological suppression among patients on antiretroviral therapy (ART) in Africa. METHODS: We conducted a cross-sectional survey with chart abstraction, patient interviews and site assessments in a nationall...

Descripción completa

Detalles Bibliográficos
Autores principales: Elul, Batya, Basinga, Paulin, Nuwagaba-Biribonwoha, Harriet, Saito, Suzue, Horowitz, Deborah, Nash, Denis, Mugabo, Jules, Mugisha, Veronicah, Rugigana, Etienne, Nkunda, Richard, Asiimwe, Anita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3541229/
https://www.ncbi.nlm.nih.gov/pubmed/23326462
http://dx.doi.org/10.1371/journal.pone.0053586
_version_ 1782255324956196864
author Elul, Batya
Basinga, Paulin
Nuwagaba-Biribonwoha, Harriet
Saito, Suzue
Horowitz, Deborah
Nash, Denis
Mugabo, Jules
Mugisha, Veronicah
Rugigana, Etienne
Nkunda, Richard
Asiimwe, Anita
author_facet Elul, Batya
Basinga, Paulin
Nuwagaba-Biribonwoha, Harriet
Saito, Suzue
Horowitz, Deborah
Nash, Denis
Mugabo, Jules
Mugisha, Veronicah
Rugigana, Etienne
Nkunda, Richard
Asiimwe, Anita
author_sort Elul, Batya
collection PubMed
description BACKGROUND: Generalizable data are needed on the magnitude and determinants of adherence and virological suppression among patients on antiretroviral therapy (ART) in Africa. METHODS: We conducted a cross-sectional survey with chart abstraction, patient interviews and site assessments in a nationally representative sample of adults on ART for 6, 12 and 18 months at 20 sites in Rwanda. Adherence was assessed using 3- and 30-day patient recall. A systematically selected sub-sample had viral load (VL) measurements. Multivariable logistic regression examined predictors of non-perfect (<100%) 30-day adherence and detectable VL (>40 copies/ml). RESULTS: Overall, 1,417 adults were interviewed and 837 had VL measures. Ninety-four percent and 78% reported perfect adherence for the last 3 and 30 days, respectively. Eighty-three percent had undetectable VL. In adjusted models, characteristics independently associated with higher odds of non-perfect 30-day adherence were: being on ART for 18 months (vs. 6 months); younger age; reporting severe (vs. no or few) side effects in the prior 30 days; having no documentation of CD4 cell count at ART initiation (vs. having a CD4 cell count of <200 cells/µL); alcohol use; and attending sites which initiated ART services in 2003–2004 and 2005 (vs. 2006–2007); sites with ≥600 (vs. <600 patients) on ART; or sites with peer educators. Participation in an association for people living with HIV/AIDS; and receiving care at sites which regularly conduct home-visits were independently associated with lower odds of non-adherence. Higher odds of having a detectable VL were observed among patients at sites with peer educators. Being female; participating in an association for PLWHA; and using a reminder tool were independently associated with lower odds of having detectable VL. CONCLUSIONS: High levels of adherence and viral suppression were observed in the Rwandan national ART program, and associated with potentially modifiable factors.
format Online
Article
Text
id pubmed-3541229
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-35412292013-01-16 High Levels of Adherence and Viral Suppression in a Nationally Representative Sample of HIV-Infected Adults on Antiretroviral Therapy for 6, 12 and 18 Months in Rwanda Elul, Batya Basinga, Paulin Nuwagaba-Biribonwoha, Harriet Saito, Suzue Horowitz, Deborah Nash, Denis Mugabo, Jules Mugisha, Veronicah Rugigana, Etienne Nkunda, Richard Asiimwe, Anita PLoS One Research Article BACKGROUND: Generalizable data are needed on the magnitude and determinants of adherence and virological suppression among patients on antiretroviral therapy (ART) in Africa. METHODS: We conducted a cross-sectional survey with chart abstraction, patient interviews and site assessments in a nationally representative sample of adults on ART for 6, 12 and 18 months at 20 sites in Rwanda. Adherence was assessed using 3- and 30-day patient recall. A systematically selected sub-sample had viral load (VL) measurements. Multivariable logistic regression examined predictors of non-perfect (<100%) 30-day adherence and detectable VL (>40 copies/ml). RESULTS: Overall, 1,417 adults were interviewed and 837 had VL measures. Ninety-four percent and 78% reported perfect adherence for the last 3 and 30 days, respectively. Eighty-three percent had undetectable VL. In adjusted models, characteristics independently associated with higher odds of non-perfect 30-day adherence were: being on ART for 18 months (vs. 6 months); younger age; reporting severe (vs. no or few) side effects in the prior 30 days; having no documentation of CD4 cell count at ART initiation (vs. having a CD4 cell count of <200 cells/µL); alcohol use; and attending sites which initiated ART services in 2003–2004 and 2005 (vs. 2006–2007); sites with ≥600 (vs. <600 patients) on ART; or sites with peer educators. Participation in an association for people living with HIV/AIDS; and receiving care at sites which regularly conduct home-visits were independently associated with lower odds of non-adherence. Higher odds of having a detectable VL were observed among patients at sites with peer educators. Being female; participating in an association for PLWHA; and using a reminder tool were independently associated with lower odds of having detectable VL. CONCLUSIONS: High levels of adherence and viral suppression were observed in the Rwandan national ART program, and associated with potentially modifiable factors. Public Library of Science 2013-01-09 /pmc/articles/PMC3541229/ /pubmed/23326462 http://dx.doi.org/10.1371/journal.pone.0053586 Text en © 2013 Elul et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Elul, Batya
Basinga, Paulin
Nuwagaba-Biribonwoha, Harriet
Saito, Suzue
Horowitz, Deborah
Nash, Denis
Mugabo, Jules
Mugisha, Veronicah
Rugigana, Etienne
Nkunda, Richard
Asiimwe, Anita
High Levels of Adherence and Viral Suppression in a Nationally Representative Sample of HIV-Infected Adults on Antiretroviral Therapy for 6, 12 and 18 Months in Rwanda
title High Levels of Adherence and Viral Suppression in a Nationally Representative Sample of HIV-Infected Adults on Antiretroviral Therapy for 6, 12 and 18 Months in Rwanda
title_full High Levels of Adherence and Viral Suppression in a Nationally Representative Sample of HIV-Infected Adults on Antiretroviral Therapy for 6, 12 and 18 Months in Rwanda
title_fullStr High Levels of Adherence and Viral Suppression in a Nationally Representative Sample of HIV-Infected Adults on Antiretroviral Therapy for 6, 12 and 18 Months in Rwanda
title_full_unstemmed High Levels of Adherence and Viral Suppression in a Nationally Representative Sample of HIV-Infected Adults on Antiretroviral Therapy for 6, 12 and 18 Months in Rwanda
title_short High Levels of Adherence and Viral Suppression in a Nationally Representative Sample of HIV-Infected Adults on Antiretroviral Therapy for 6, 12 and 18 Months in Rwanda
title_sort high levels of adherence and viral suppression in a nationally representative sample of hiv-infected adults on antiretroviral therapy for 6, 12 and 18 months in rwanda
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3541229/
https://www.ncbi.nlm.nih.gov/pubmed/23326462
http://dx.doi.org/10.1371/journal.pone.0053586
work_keys_str_mv AT elulbatya highlevelsofadherenceandviralsuppressioninanationallyrepresentativesampleofhivinfectedadultsonantiretroviraltherapyfor612and18monthsinrwanda
AT basingapaulin highlevelsofadherenceandviralsuppressioninanationallyrepresentativesampleofhivinfectedadultsonantiretroviraltherapyfor612and18monthsinrwanda
AT nuwagababiribonwohaharriet highlevelsofadherenceandviralsuppressioninanationallyrepresentativesampleofhivinfectedadultsonantiretroviraltherapyfor612and18monthsinrwanda
AT saitosuzue highlevelsofadherenceandviralsuppressioninanationallyrepresentativesampleofhivinfectedadultsonantiretroviraltherapyfor612and18monthsinrwanda
AT horowitzdeborah highlevelsofadherenceandviralsuppressioninanationallyrepresentativesampleofhivinfectedadultsonantiretroviraltherapyfor612and18monthsinrwanda
AT nashdenis highlevelsofadherenceandviralsuppressioninanationallyrepresentativesampleofhivinfectedadultsonantiretroviraltherapyfor612and18monthsinrwanda
AT mugabojules highlevelsofadherenceandviralsuppressioninanationallyrepresentativesampleofhivinfectedadultsonantiretroviraltherapyfor612and18monthsinrwanda
AT mugishaveronicah highlevelsofadherenceandviralsuppressioninanationallyrepresentativesampleofhivinfectedadultsonantiretroviraltherapyfor612and18monthsinrwanda
AT rugiganaetienne highlevelsofadherenceandviralsuppressioninanationallyrepresentativesampleofhivinfectedadultsonantiretroviraltherapyfor612and18monthsinrwanda
AT nkundarichard highlevelsofadherenceandviralsuppressioninanationallyrepresentativesampleofhivinfectedadultsonantiretroviraltherapyfor612and18monthsinrwanda
AT asiimweanita highlevelsofadherenceandviralsuppressioninanationallyrepresentativesampleofhivinfectedadultsonantiretroviraltherapyfor612and18monthsinrwanda